Built to provide research that’s more actionable and strategically valuable, The Business Research Company’s 2026 market reports include market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, broader supply chain intelligence, emerging startup tracking, and in-depth product insights.
#PD-L1 And PIK3CA Testing Market Set To Climb From $1.93 Billion In 2026 To $3.4 Billion By 2030#_x000D_
The pd-l1 and pik3ca testing market size has experienced significant expansion in recent years. It is projected to grow from $1.67 billion in 2025 to $1.93 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 15.5%. This historical growth can be linked to the development of pd-l1 and pik3ca assays, their increasing adoption in clinical trials, the rising prevalence of cancer, ongoing advancements in molecular diagnostics, and a heightened awareness of personalized therapy._x000D_
_x000D_
The pd-l1 and pik3ca testing market size is anticipated to experience substantial growth in the upcoming years. It is predicted to reach $3.4 billion in 2030, demonstrating a compound annual growth rate (CAGR) of 15.2%. This expansion throughout the forecast period is driven by factors such as the integration of AI in biomarker detection, the increasing application of liquid biopsy, advancements in precision oncology, strategic partnerships between diagnostics and pharmaceutical companies, and regulatory approvals for next-generation assays. Key trends observed in the forecast duration include targeted cancer biomarker testing, AI-based mutation analysis, the wider adoption of liquid biopsy, integration with drug development processes, and high-throughput genomic screening._x000D_
_x000D_
#Get A Free Sample Report With In-Depth Market Insights:#_x000D_
_x000D_
#PD-L1 And PIK3CA Testing Market Demand Drivers: What’s Powering Industry Growth?#_x000D_
The rising incidence of cancer is projected to drive the expansion of the PD-L1 and PIK3CA testing market in the future. Cancer is a condition marked by the uncontrolled proliferation and spread of abnormal cells within the body, capable of invading surrounding tissues and potentially metastasizing to other regions. This increased cancer prevalence is attributed to escalating lifestyle-related risks and aging populations, which are leading to higher rates of diagnosis and an increased demand for early detection and efficient treatment solutions. PD-L1 and PIK3CA testing facilitates cancer management by enabling accurate diagnosis and guiding targeted medications, which helps tailor treatment regimens for individual patients and improves clinical outcomes. For instance, in September 2024, the American Cancer Society, a US-based non-profit organization, reported that global cancer cases in men are anticipated to surge by 84% by 2029, increasing from 10.3 million in 2022 to 19 million. Therefore, the growing prevalence of cancer is fueling the growth of the PD-L1 and PIK3CA testing market._x000D_
_x000D_
#PD-L1 And PIK3CA Testing Market Segmentation And Category Overview#_x000D_
The pd-l1 and pik3ca testing market covered in this report is segmented – _x000D_
_x000D_
1) By Test Type: Immunohistochemistry, Next-Generation Sequencing, Polymerase Chain Reaction_x000D_
2) By Sample Type: Tissue Samples, Liquid Biopsy Samples_x000D_
3) By Applications: Cancer Diagnosis, Drug Development, Research, Other Applications_x000D_
4) By End User: Hospitals And Clinics, Laboratories, Pharmaceutical Companies_x000D_
_x000D_
Subsegments:_x000D_
1) By Immunohistochemistry: Tissue Staining, Protein Expression Analysis_x000D_
2) By Next-Generation Sequencing: Whole Genome Sequencing, Targeted Gene Sequencing, Exome Sequencing, Ribonucleic Acid (RNA) Sequencing_x000D_
3) By Polymerase Chain Reaction: Quantitative Polymerase Chain Reaction, Digital Polymerase Chain Reaction_x000D_
_x000D_
#PD-L1 And PIK3CA Testing Market Innovation Trends: What Developments Are Reshaping The Industry?#_x000D_
Companies operating significantly in the PD-L1 and PIK3CA testing market are concentrating on technological breakthroughs, such as the integration of companion diagnostics, to enhance therapeutic targeting, improve treatment effectiveness, and support personalized medicine strategies in oncology. Companion diagnostic integration refers to advanced, technology-driven testing frameworks developed in conjunction with specific medicines to identify patient groups most likely to benefit from particular treatments based on their unique biomarker profiles. For instance, in October 2024, F. Hoffmann-La Roche AG, a biotechnology and pharmaceutical company located in Switzerland, launched Itovebi (inavolisib) in combination with palbociclib and fulvestrant. This was intended for adults with endocrine-resistant, PIK3CA-mutated, HR-positive, HER2-negative advanced or metastatic breast cancer. The Food and Drug Administration (FDA), a US-based federal agency, approved this regimen, basing its decision on the pivotal Phase III INAVO120 study. This study revealed that the regimen more than doubled progression-free survival compared with palbociclib and fulvestrant used alone. It also marks Roche’s initial targeted therapy for HR-positive disease and includes a companion diagnostic to pinpoint eligible patients, signifying a major advance in precision medicine for a patient population facing limited first-line treatment options._x000D_
_x000D_
#PD-L1 And PIK3CA Testing Market Key Players Shaping Industry Direction#_x000D_
Major companies operating in the pd-l1 and pik3ca testing market are F. Hoffmann-La Roche AG, Thermo Fisher Scientific Inc., Abbott Laboratories, Laboratory Corporation of America Holdings (Labcorp), Quest Diagnostics Incorporated, Eurofins Scientific SE, Agilent Technologies Inc., Sonic Healthcare Limited, Illumina Inc., Bio-Rad Laboratories Inc., QIAGEN N.V., Myriad Genetics Inc., NeoGenomics Laboratories Inc., BGI Genomics Co. Ltd., Guardant Health Inc., Caris Life Sciences, Foundation Medicine Inc., Amoy Diagnostics Co. Ltd., ACCB Biotech Private Limited, EntroGen Inc. _x000D_
_x000D_
#View The Full PD-L1 And PIK3CA Testing Market Report:#_x000D_
_x000D_
#PD-L1 And PIK3CA Testing Market Regional Analysis: Which Region Leads By Revenue?#_x000D_
North America was the largest region in the PD-L1 and PIK3CA testing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the pd-l1 and pik3ca testing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa._x000D_
_x000D_
#Reach Out To Our Team:#_x000D_
_x000D_
The Business Research Company: https://www.thebusinessresearchcompany.com/_x000D_
Americas: +1 310-496-7795_x000D_
Asia: +44 7882 955267 & +91 8897263534_x000D_
Europe: +44 7882 955267_x000D_
Email us at: marketing@tbrc.info_x000D_
_x000D_
#Follow us on:#_x000D_
_x000D_
LinkedIn: https://in.linkedin.com/company/the-business-research-company_x000D_
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ_x000D_
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Wasay has over a decade of experience in market research, data modelling, and analytics, with prior experience at GlobalData and Decision Tree Consulting Services. At The Business Research Company , he leads research operations across syndicated studies, customized consulting engagements, and the Global Market Model platform. His professional experience includes supporting organizations such as Boston Consulting Group, KPMG, and Ernst & Young. Wasay holds a degree in Electronics and Communications Engineering, postgraduate management qualifications from International Management Institute Belgium and Indian School of Business and Entrepreneurship, and completed the Integrated Program in Business Analytics from Indian Institute of Management Indore.